Pediatric solid organ transplant recipients are at risk for Epstein-Barr virus (EBV)-driven lymphoproliferative disease. The expression of 5 sentinel EBV genes (EBNA1, EBNA2a, LMP1, LMP2a, and ZEBRA) was examined in solid organ transplant recipients who developed persistent virus loads in their peripheral blood lymphocytes after transplantation. Two distinct groups were identified. LMP2a gene expression alone was detected among 12 of 14 patients carrying EBV loads р100 copies/10 5 lymphocytes. The other 2 low-load carriers made LMP2a RNA but also expressed LMP1 RNA. In contrast, LMP2a and LMP1 gene expression was detected among 11 of 13 patients carrying a virus load 1100 copies/10 5 lymphocytes. Two high-load carriers made LMP1 RNA but not the RNA for LMP2a or any of the other viral genes. Therefore, persistent low-load carriers appear to maintain an apparently normal state of latent viral infection, whereas high-load carriers display a unique LMP1:LMP2a pattern of viral gene expression that has not been previously described.
Pediatric solid organ transplant recipients are at risk for Epstein-Barr virus (EBV)-driven lymphoproliferative disease. The expression of 5 sentinel EBV genes (EBNA1, EBNA2a, LMP1, LMP2a, and ZEBRA) was examined in solid organ transplant recipients who developed persistent virus loads in their peripheral blood lymphocytes after transplantation. Two distinct groups were identified. LMP2a gene expression alone was detected among 12 of 14 patients carrying EBV loads р100 copies/10 5 lymphocytes. The other 2 low-load carriers made LMP2a RNA but also expressed LMP1 RNA. In contrast, LMP2a and LMP1 gene expression was detected among 11 of 13 patients carrying a virus load 1100 copies/10 5 lymphocytes. Two high-load carriers made LMP1 RNA but not the RNA for LMP2a or any of the other viral genes. Therefore, persistent low-load carriers appear to maintain an apparently normal state of latent viral infection, whereas high-load carriers display a unique LMP1:LMP2a pattern of viral gene expression that has not been previously described. [1] . Although most primary infections have an asymptomatic presentation and are resolved by cell-mediated immunity in immunocompetent hosts, EBV-driven B cell proliferation can progress to immunoblastic lymphoma in immunosuppressed transplant recipients [2] [3] [4] [5] [6] [7] . Persons at greatest risk are transplant recipients undergoing primary EBV infection while receiving an immunosuppressive drug regimen. EBV-driven posttransplant lymphoproliferative disease (PT-LPD) is associated with a very high circulating EBV load [8] [9] [10] [11] [12] [13] . In a significant number of transplant recipients, clinical resolution of primary infection results in a chronic carrier state, in which high copy numbers of EBV persist in the peripheral blood for months or in some cases years [11, 14] (authors' unpublished data).
Epstein-Barr virus (EBV) is a ubiquitous virus that establishes lifelong infection in most humans
To understand the pathogenesis of EBV-driven PT-LPD, it is essential to characterize the viral gene expression associated with the high virus load carrier state that develops in an immunosuppressed host. The interaction of EBV with B lymphocytes in the course of normal infection may be characterized as existing in 1 of 3 different states that are distinguishable by the pattern of viral gene expression. The first is a latent and/ or resting state in which the mRNA for the LMP2a (latent membrane protein 2a) gene is the only viral transcript that is consistently detected by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis in the peripheral blood of healthy latently infected persons. The second is an immortalized and/ or continuously proliferating state characterized by the expression of at least 10 viral genes (Epstein-Barr nuclear antigen [EBNA]1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNALP, LMP1 and LMP2, EBER1 and EBER2), of which 6 (EBNA1, EBNA2, EBNA3A, EBNA3C, EBNALP, and LMP1) have been directly implicated in the process of immortalization. The third is a virus-producing and/or lytic state characterized by the expression of 160 early and capsid structural genes and initiated by the expression of the ZEBRA (or Zta) gene, which acts as EBV's immediate early transcriptional activator [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] .
RNA transcription and protein analyses have identified EBV genes expressed in various human malignancies. In Burkitt's lymphoma, only EBNA1 is believed to be expressed, whereas in posttransplant lymphomas, EBNA1 and -2 and LMP1 have been detected [29, 30] . In nasopharyngeal carcinomas, EBNA1, LMP1, LMP2a, and a family of transcripts from the region of the BamH1 A fragment are expressed [31] . To understand the contributing role of EBV gene expression in the pathogenesis of a tumor, it is crucial to study the interaction early in the development of the disease. Immunosuppressed persons with solid organ transplants provide a unique opportunity to prospectively study the virus interacting with a host at high risk for the development of an LPD or malignant lymphoma. In the current study, we examined the state of EBV gene expression in im- Figure 1 . Diagrams of RNA structures show location of reverse transcriptase-polymerase chain reaction (RT-PCR) targets for amplification of sentinel Epstein-Barr virus (EBV) genes used in this study. Bar represents cDNA sequence; exon-exon borders are shown as vertical lines dividing bars into segments. Gray region within each cDNA is the open-reading frame that encodes the gene product. Locations of primary and secondary PCR targets appear above and below the cDNA, respectively. At right are RT-PCR reaction products from a dilution series that represent X50-7 cell equivalents in 10 5 BJAB background, to simulate a decreasing number of EBV-positive cells in a constant background. For the BZLF.1 target, B95-8CR cells were induced into virus production with TPA and butyrate and were used in place of X50-7 cells. munocompromised transplant recipients who developed persistent virus loads in their peripheral blood lymphocytes (PBL).
Materials and Methods
Patients. Since 1995, we have obtained the EBV loads of 1800 transplant recipients by using a quantitative competitive (QC)-PCR protocol developed in our laboratory [9] . Blood specimens of 2-3 mL were layered onto ficoll-hypaque (Histopaque 1077; Sigma, St. Louis) and were processed into lymphocytes and plasma. Viral DNA loads were determined from the lymphocyte fraction. The QC-PCR assay for EBV was used to quantitate virus loads of 8-5000 copies of viral DNA in 10 5 lymphocytes. Normal latent infection (0.01-0.1 copies/10 5 lymphocytes) was not detected by this protocol. Prospective monitoring has shown that an increasing EBV load was detected in lymphocyte preparations 2-4 weeks before a diagnosis of disease [7, 32, 33] . Because the protocol is relatively new, virus load measurements have not been published in significant numbers of immunosuppressed hosts over prolonged periods. One striking observation from the data collected (to be analyzed and published separately) is the development and persistence of asymptomatic chronic virus loads in 150% of the patients. After an EBV infection, many patients persistently carry detectable low viral DNA loads (defined as р100 genome copies/ 10 5 lymphocytes) or, more rarely, may carry very high virus loads (defined as 1200 EBV genome copies/10 5 lymphocytes) in their peripheral blood for periods of 2 months to several years, with generally no clinical manifestation.
The current analysis focused on the pediatric transplant population, because within this group there are 1190 patients with mul- tiple prospectively collected specimens. Among 65 patients (34.2%), virus load has never been detectable. A persistent low load was detected in 69 patients (36.3%), whereas a persistent high load was detected in 35 patients (18.4%). In the remaining 21 patients, virus loads have fluctuated. Persistent low-load and persistent high-load carriers were initially selected from this population if there were sufficient cells archived for RNA analysis. In this study, we selected 14 persistent low-load carriers (defined as р100 genome copies/10 5 lymphocytes; stable for 3 months) and 13 persistent high-load carriers (1200 genome copies/10 5 lymphocytes; stable for 3 months) as study populations.
Cell lines. X50-7 and B95-8 cell lines (gifts of G. Miller, Yale University, New Haven, CT) are widely used for studies on immortalization and virus production. BJAB is an EBV-negative B cell lymphoma used as a virus-negative control and as carrier cells. For RT-PCR analysis of EBNA1, EBNA2, LMP1, and LMP2a, RNA extracted from X50-7 was used as a positive control. For RT-PCR analysis of ZEBRA transcript, RNA from induced B95-8 (with 20 ng/mL of TPA and 3 mM Na butyrate) was used as a control. All cell lines were maintained in 5% CO 2 with 10% fetal calf serum, RPMI 1640, penicillin, and streptomycin.
RNA extraction and RT-PCR. Total RNA isolation reagent (TRIZOL; Gibco BRL, Gaithersburg, MD) was used to extract RNA from frozen PBL. RNA isolated from these cells was digested with RQ1 DNase (Promega, Madison, WI) before analysis, to remove residual cellular DNA. cDNA reactions were performed on the RNA extracted from PBL. We used 5 mg of RNA in 6 ∼ 2 ϫ 10 a reaction mixture consisting of 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2.5 mM MgCl 2 , 10 mM dithiothreitol, 20 pmol of each of the 3 primer oligonucleotides, 200 mM of each dNTP, 1 U of RNAsin RNase inhibitor (Promega), and 200 U of Superscript II reverse transcriptase (Gibco BRL). The total 25-mL reaction was incubated at 48ЊC for 50 min. To remove RNA complementary to the cDNA, 1 U of RNase H was added to the cDNA reaction mixture and incubated at 37ЊC for 20 min. The quality of the RNA and cDNA reaction was tested with b-actin host gene expression control target. After RT, the reaction mixtures were amplified through PCR by use of primers for primary amplification for all 5 targets. In PCR, the 5 and 3 primers were adjusted to 20 pmol/reaction in 1.5 mM Tris-HCl, pH 8.0, 50 mM KCl, 2.5 mM MgCl 2 , 200 mM of each dNTP, and 1.25 U of DNA polymerase (AmpliTaq Gold; PerkinElmer, Norwalk, CT). We subjected 50-mL reaction volumes to 25 cycles of temperature variation (94ЊC for 30 s, 52ЊC for 30 s, then 72ЊC for 30 s) in a PCR system (GeneAmp 9600; Perkin-Elmer). Secondary PCR reactions were performed by use of a 1:50 ratio of primary PCR product and the individual nested primer sets for each target. The buffer conditions were identical to those for the primary PCR, and 35 cycles of PCR were done. Products were analyzed on 2.5% agarose gels containing 0.5ϫ Tris-borate-EDTA electrophoresis buffer. All of the target sequences were detected by 32 P-labeled oligonucleotide probes of Southern blots.
Results
mRNA target structure and detection sensitivity. Five key viral genes (LMP2a, EBNA1, EBNA2, LMP1, and ZEBRA) were selected as the minimum number of RT-PCR targets to study the virus:host cell interaction (figure 1). Analyses of the pattern of expression of these genes may be used to infer the [19] [20] [21] [22] [23] . Expression of the EBNA1 gene is required for maintenance of virus episomes in proliferating virus-immortalized B cells, because it directs the origin of plasmid replication-mediated replication of episomes at the S phase of the cell cycle [34] . EBNA2 and LMP1 are essential for the proliferative phenotype of infected B cells [15] . Detection of these 2 gene transcripts in PBL is, therefore, indicative of an EBV-driven proliferative state in the peripheral circulation. EBNA1, EBNA2, and LMP1 are also differentially expressed in many virus-associated diseases and tumors [1, 30, 31, 35, 36] . Differential EBNA2 and/or LMP1 gene expression is consistent with an abnormal state of the virus-host interaction, and detection of this abnormality may provide an important clue to understanding the origins and consequences of virus loads in immunocompromised hosts [30] . The ZEBRA immediate early transcriptional activator initiates a lytic virusproductive state, and RT-PCR detection of ZEBRA messages indicates that a virus productive state is present and, in some cases, whether antiviral drug therapy is working [27, 28] . The RT-PCR target sequences for each of these RNAs contain exon-exon junctions (figure 1). The location of primers for RT-PCR analysis was selected and optimized for PCR amplification using RNA from cell lines B95-8 and X50-7 ( figure 1  and table 1) . Two sets of primers were designed for each target, which allowed for a nested RT-PCR for multiple targets from small samples. The sensitivity of the nested primer reaction for each target was tested by amplifying the target from 1, 10, 100, and 1000 EBV-positive cell equivalents against a background of 10 5 EBV-negative BJAB cells ( figure 1) . Detection of viral RNA from the equivalent of 1 positive cell was achieved for all the targets under these amplification conditions. Although extremely sensitive, the assay gave no indication of the relative number of copies of each RNA.
EBV RNA analysis in persistent low-load carriers. In the group of 14 persistent low-loads carriers, virus loads were р100 copies/10 5 lymphocytes for 13 months (range, 3-24 months), and all patients were clinically healthy. "Low" is a relative term used here to differentiate this group from the "high"-load carriers. It is important to make this distinction, because both patient groups carry high virus loads relative to the load carried by immunocompetent hosts. In patient 1, the virus load was at or below the detection limits of the assay (1 infected cell/10 5 lymphocytes). The DNA PCR assay measures load in 10 5 PBL, whereas the RNA PCR assay samples cells. Of 13 pa- 6 2 ϫ 10 tients in the low-load group, 11 had no history of PT-LPD (table 2) . Three patients (patients 2, 6, and 7) had diagnoses of PT-LPD at 4, 10, and 9 months before the specimen date, respectively. Among 12 of 14 specimens tested, only the mRNA for LMP2a was detected (table 3) . There was no detectable expression of any of the other viral genes (EBNA1, EBNA2, LMP1, or ZEBRA). Among 2 of these 14 specimens, LMP1 and LMP2a were detected, a result that is better interpreted in light of the gene expression found in the high-load carriers. Specimens from low-load carriers obtained months apart gave the same results. Therefore, persistent low-load carriers maintain their virus load in a latent state that is similar, if not identical, to the latent state that is maintained in immunocompetent carriers.
EBV RNA analysis in high-load carriers. We selected 13 clinically asymptomatic patients (patients 15-27) with high virus loads (1100 copies/10 5 lymphocytes for 13 months; table 2). Of the 13 patients, 8 had a prior diagnosis of PT-LPD, and 5 had no previous diagnosis of LPD. Among those with a history of PT-LPD, 7 of 8 specimens were collected after the PT-LPD, and 1 specimen (patient 21) was sampled 1009 days before PT-LPD developed. Eleven of 13 patients in this category were positive for LMP2a gene expression (table 3). All were positive for LMP1 gene expression. No known clinical events were associated with the differential EBV gene expression seen in patients 20 (positive for EBNA1, LMP1, and 
NOTE. Ϫ, negative; ϩ, positive; ND, not done. (table 4) .
Limiting dilution estimates of relative abundance of viral messages. The results presented so far were collected by optimizing the PCR reactions to detect the presence of any of the targeted mRNA molecules. The tendency when viewing tables of positive and negative scores is to assign all positives equal significance. Semiquantitative measurement of the relative RNA abundances allows for an assessment of the heterogeneity of the cell population. When semiquantitative analysis is conducted on serially obtained specimens, changes in the relative abundances can be compared with changes in the virus load. In control experiments, (table  1) . These results indicated that 2-10 copies of EBNA1, EBNA2, LMP2a, and ZEBRA messages were detected, compared with 160 detected copies of LMP1. Therefore, adding a limiting dilution step before the amplification procedure can be used to detect large-scale differences in relative mRNA abundances in complex specimens that contain as few as 10 cells.
Limiting dilution analyses of the viral gene expression in the high-load carriers revealed that the amounts of LMP1 RNA were 5-100 times greater than the amounts of LMP2a RNA ( figure 2 and table 5 ). This disparity in the level of gene expression for these 2 membrane proteins is similar to that detected in lymphoblastoid cell lines [37] . Semiquantitative analysis of viral gene expression from consecutively collected specimens showed a pattern in which the level of expression increased as virus load increased over time (patients 21 and 29) 
NOTE. EBV, Epstein-Barr virus; PBL, peripheral blood lymphocytes; ND, not done; Ϫ, negative; ϩ, positive.
and, conversely, viral gene expression decreased when virus loads decreased (patient 28; table 5). There was always a relatively higher proportion of LMP1 gene expression, compared with that of LMP2a. Therefore, it appeared that, despite the clinical setting (before or after PT-LPD) or whether virus load was increasing, stable, or falling, the LMP1:LMP2a expression ratio always favored LMP1. When some of the other viral genes being surveyed were detected (EBNA1, EBNA2, and ZEBRA RNAs), the amounts of both the LMP1 and LMP2a RNA were always greater by a factor у5. These results provide a preliminary basis for interpreting the positive and negative values provided in the nonquantitative tables (tables 3 and 4) of QC-PCR detection of viral RNAs in the low and high chronic virus load carriers.
EBV gene expression in LPD. The patterns of viral gene expression in the persistent carriers suggest that different states of the virus-host interaction occur in a load-related manner. Low-load carriers appear to carry virus in a latent state similar to that observed in immunocompetent hosts. High-load carriers display a unique state of virus-host interaction characterized by persistent LMP1 and LMP2a expression and variable expression of other viral genes. Comparison of these expression patterns with the pattern observed during LPD may reveal distinguishing features of active disease that could be used to supplement virus load measurements as a diagnostic marker.
We obtained specimens from 8 patients just before or immediately after (range, Ϫ35 to ϩ14 days) the clinical diagnosis of PT-LPD (table 6). As expected from previous studies, viral DNA load was high at the time of the disease. The pattern of viral gene expression consistently showed LMP2a (8 of 8) and EBNA2 (8 of 8); most specimens also expressed LMP1 (6 of 8) and EBNA1 (5 of 6), but ZEBRA was detected less frequently (3 of 8; table 6). The overall pattern is suggestive of an actively productive EBV infection and is similar to the pattern detected in patient 32. Patient 32 had a diagnosed active EBV infection coincident with a specimen processed for RNA analysis that was positive for all viral RNA products (data not shown). This pattern suggests that there are B cells that express the virus immortalization program in the peripheral circulation before and at the time of a PT-LPD diagnosis. These results agree with previous findings of detection of proliferative and replicative transcripts in tumor tissue of PT-LPD [30] .
Discussion
We analyzed EBV gene expression in long-term, persistent, high-and low-load carrier states in transplant recipients. In contrast to a previous report, we found that some form of viral gene expression was always detectable in transplant recipients carrying EBV loads, and we did not find evidence for a state of viral latency in which none of the known immortalizationand/or latency-associated viral genes were expressed [14] . Two distinct groups relating virus load to gene expression were identified. Patients carrying р100 EBV copies/10 5 lymphocytes displayed a state of viral infection transcriptionally indistinguishable from the latency that has been described in healthy persons [19] . This normal latency is characterized by expression of the LMP2a spliced transcript from a viral genome that is exclusively carried in resting memory B cells (defined as CD19 cell populations from low load-carrying immunocompromised patients are consistent with the load being carried in the memory B cell compartment [14] (unpublished data). Thus, aside from the load being 3 or 4 orders of magnitude greater than normal, these low-load carriers appear to have an essentially normal latent virus-host cell interaction. The pattern of viral gene expression observed in the high-load (1200 copies/10 5 lymphocytes) carriers is characterized by the expression of LMP2a and LMP1. We observed sporadic detection of the other viral genes (EBNA1, EBNA2, and ZEBRA) in the cross-sectional and serially collected specimens. The semiquantitative analysis of viral gene expression showed that, when detected, the EBNA1, EBNA2, and ZEBRA genes were expressed at a much lower level than were LMP2a or LMP1. The sporadic nature and low levels of expression suggest that, on the occasions when expression of EBNA1, EBNA2, and ZEBRA genes was detected, the population of virus-carrying cells in circulation was likely to have been heterogeneous, with only a few of the viruspositive cells that express the EBNA1, EBNA2, and/or ZEBRA RNAs. The expression profile of circulating cells with respect to the LMP1 and LMP2a genes is more difficult to assess. Of 40 specimens collected, 2 showed LMP1-only expression. This could be taken as evidence for an LMP1-only expression state, or it could be due to a problem with LMP2a RNA detection in samples with poor RNA quality. Limiting dilution RT-PCR analyses showed that whenever LMP1 RNA was present, it was at a 10-fold higher concentration than other viral RNAs. Therefore, LMP1 RNA would be more likely to survive in poor quality RNA preparations and give rise to an LMP1-only result. Amplifications of control actin RNA from the specimens that had yielded the LMP1-only expression did not appear to differ from the other specimens, which suggests that RNA quality was not the reason for the lack of LMP2a detection. Differential LMP1 and LMP2a expression remains a distinct possibility and leads directly to the notion that some high-load carrier states could be due to a heterogeneous population of virus-infected cells and composed of a mixture of LMP2a-and LMP1-only-expressing cells.
On the other hand, the semiquantitative RNA expression analysis showed that the levels of LMP1 and LMP2a RNAs increased and decreased along with viral DNA loads, whereas the ratio of the levels of LMP1:LMP2a RNA did not change (table 5) . LMP1 expression was always much higher than that of LMP2a. This pattern would seem more likely to occur in a population of virus-infected cells that was homogeneous with most or all cells that express both genes. Because this question of heterogeneity is crucial to understanding the nature and dynamics of high virus loads, further in situ analyses will be necessary to determine directly what viral proteins the infected cells are making.
Viral gene expression in LPD has mostly been studied in biopsy specimens of the disease-affected tissues and shows a heterogeneous pattern of expression of genes associated with B cell immortalization and virus production [30] . We examined how this might be reflected in the patterns of viral gene expression detected in the peripheral circulation by PCR analysis and the use of our panel of marker genes. EBNA1, EBNA2, LMP1, and LMP2a were often detected in specimens collected close to the diagnosis of PT-LPD. Among these, EBNA2 and LMP2a were the most consistently detectable gene products (table 6 ). Because EBNA2 expression was not associated with either the persistent high-load or the persistent low-load carrier states, this finding suggests that an assay based on detection of EBNA2 gene expression may be useful in distinguishing a load carrier state from an active disease process. Although EBNA2 expression was not detected in the low-load carrier state in this study, it was occasionally present in the high-load carriers during serial sampling. In these cases, instead of being viewed as a "false positive," another interpretation might be that the presence of EBNA2-positive cells is actually evidence of an occult reactivation of disease. Persistent high-load carriers with intermittent or persistent peripheral blood EBNA2 expression might be at greatly increased risk of developing frank disease. This view would also suggest that the state of the virus infection in the persistent high-load carriers might be more dynamic than has been revealed by measurements of viral DNA loads.
